Invention Grant
- Patent Title: Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
-
Application No.: US17199205Application Date: 2021-03-11
-
Publication No.: US11359023B2Publication Date: 2022-06-14
- Inventor: Jon Weidanz , Katherine Upchurch-Ange
- Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
- Applicant Address: US CT Ridgefield
- Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
- Current Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
- Current Assignee Address: US CT Ridgefield
- Agency: Goodwin Procter LLP
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K38/08
Abstract:
Provided herein are antibodies that selectively bind to complex comprising a non-classical HLA-I (e.g. HLA-E) and a neoantigen having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) as disclosed herein, as well as methods and uses thereof.
Public/Granted literature
- US20210371532A1 ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN AND THEIR METHODS OF USE Public/Granted day:2021-12-02
Information query
